Experts Video Reports: Neuroendocrine Tumours track
Learn about key results illustrated by slides from the sessions!
Neuroendocrine Tumours track 2022. The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.
ESMO 2021 Expert Video Report on NETs
Speaker: Rocio Garcia-Carbonero
Reporting from the ESMO Congress 2021, Rocio Garcia-Carbonero summarises the interesting results presented in the NETs track including the phase III SPINET study testing lanreotide autogel/depot in patients with advanced lung NETs, response and PFS results from the AXINET study testing axitinib plus octreotide LAR in patients with grade 1-2 extrapancreatic NETs, and the GCO-001 NIPINEC of nivolumab+ipilimumab in pre-treated patients with advanced refractory pulmonary or GEP poorly differentiated NECs, designed to explore the efficacy of immunotherapy in this setting.
Expert video Report on Neuroendocrine Tumours
Speaker: Philippe Ruszniewski
Reporting from ESMO Congress 2019, Philippe Ruszniewski comments on results of 3 studies that evaluated the effects of the addition of radioembolisation to peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumours (NETs), doubling a dose of lanreotide in patients with pancreatic or midgut NETs who progressed on conventional dosage, and the efficacy and safety of novel tyrosine kinase inhibitor surufatinib in well-differentiated advanced extrapancreatic NETs.
Expert video report on Neuroendocrine neoplasms: From biology to treatment novelties
Speaker: Nicola Fazio
Nicola Fazio provides an overview of the current state of the art regarding the management of neuroendocrine neoplasms by reviewing tumour biology and recent novelties in diagnostic imaging methods, and concluding with the adoption of treatment novelties into clinical practice.
Expert video report on clinical management of gastroenteropancreatic neuroendocrine neoplasms
Speaker: Chris Verslype
Chris Verslype explains that the management of gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) should rely on pathology findings on how well differentiated the tumour is, and the level of proliferation marker Ki67. He describes treatment options and follow-up plan recommendations according to disease staging.
Expert video report on Carcinoid Syndrome
Speaker: Juan Valle
Juan Valle explains that some patients with neuroendocrine tumours suffer from carcinoid syndrome characterised by very specific symptoms. He stressed out why it is important to detect it, and details its physiopathology, how carcinoid syndrome should be managed and what are the available treatments.
More ESMO videos on Endocrine and Neuroendocrine Cancers from the ESMO Channel